CClinicalTrials.gg
CompletedNCT04117906Updated Aug 20, 2020

Developing and Piloting an Online, Self-help Intervention (STAGE) for Anxiety

An interventional study of STAGE training for anxiety in Anxiety, sponsored by Canterbury Christ Church University. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-20.

Sponsored by Canterbury Christ Church University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study pilots a novel, brief, online, self-help training course for anxiety management, aimed at adults experiencing moderate to moderately-severe anxiety.

Read the detailed description

This study is a pilot randomised controlled trial (RCT) comparing a brief, online self-help, anxiety management training course ('STAGE') with a wait-list control. A battery of self-report measures will be administered online at baseline (week 0), post-intervention (week 3) and at follow-up (week 5).

02

Conditions studied

  • Anxiety

Browse trials for

03

In context

Anxiety Disorders

4,864 studies on the registry are indexed under Anxiety Disorders; 1,388 are open to participants now.

This study's enrollment of 77 is close to the median of 80 across 4,170 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Canterbury Christ Church University is the lead sponsor of 27 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • having a score, at baseline, on the Generalised Anxiety Disorder 7 (GAD-7) scale of between 8 and 15, inclusive;
  • having regular internet access;
  • being based in the UK.

Exclusion criteria

Exclusion Criteria:

  • significant risk issues in the last year;
  • currently receiving another psychological intervention, whether it be self-help or face-to-face;
  • having recently (within the last six months) completed a psychological intervention.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    STAGE course

    Behavioral: STAGE training for anxiety

  • No intervention
    Wait-list control

    The wait-list control group will receive access to the STAGE course after the trial is complete.

Interventions

  • BehavioralSTAGE training for anxiety

    STAGE is a brief, online, self-help course designed to target anxiety through providing training in perspective broadening and self-distancing.

06

What researchers measure

Primary outcomes

  1. Change from baseline (week 0) at post-intervention (week 3) on the Generalised Anxiety Disorder 7 (GAD-7) scale.

    The Generalised Anxiety Disorder 7 (GAD-7) scale is a self-report measure of general anxiety, producing a total score between 0 and 21, with higher scores indicating greater levels of general anxiety.

    Time frame: Post-intervention (3 weeks after baseline).

Secondary outcomes

  1. Change from baseline (week 0) at follow-up (week 5) on the Generalised Anxiety Disorder 7 (GAD-7) scale.

    As described above

    Time frame: Follow-up (5 weeks after baseline).

  2. Change from baseline (week 0) at post-intervention (week 3) on the Patient Health Questionnaire 9 (PHQ-9).

    The Patient Health Questionnaire 9 (PHQ-9) is a self-report measure of depression, producing a total score between 0 and 27, with higher scores indicating greater levels of depression.

    Time frame: Post-intervention (3 weeks after baseline).

  3. Change from baseline (week 0) at follow-up (week 5) on the Patient Health Questionnaire 9 (PHQ-9).

    As described above

    Time frame: Follow-up (5 weeks after baseline).

  4. Change from baseline (week 0) at post-intervention (week 3) on the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS).

    The Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) is a self-report measure of mental wellbeing, producing a total score between 14 and 70, with higher scores indicating greater levels of mental wellbeing.

    Time frame: Post-intervention (3 weeks after baseline).

  5. Change from baseline (week 0) at follow-up (week 5) on the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS).

    As described above

    Time frame: Follow-up (5 weeks after baseline).

  6. Change from baseline (week 0) at post-intervention (week 3) on the Experience Questionnaire (EQ).

    The Experience Questionnaire (EQ) is a self-report measure of decentering, producing a total score between 20 and 100, with higher scores indicating greater levels of decentering.

    Time frame: Post-intervention (3 weeks after baseline).

  7. Change from baseline (week 0) at follow-up (week 5) on the Experience Questionnaire (EQ).

    As described above

    Time frame: Follow-up (5 weeks after baseline).

  8. Change from baseline (week 0) at post-intervention (week 3) on the Putting into Perspective subscale of the Cognitive Emotion Regulation Questionnaire (CERQ).

    The Putting into Perspective subscale of the Cognitive Emotion Regulation Questionnaire (CERQ) is a self-report measure of perspective taking, producing a total score between 4 and 20.

    Time frame: Post-intervention (3 weeks after baseline).

  9. Change from baseline (week 0) at follow-up (week 5) on the Putting into Perspective subscale of the Cognitive Emotion Regulation Questionnaire (CERQ).

    As described above

    Time frame: Follow-up (5 weeks after baseline).

07

Study locations

1 site
  • Canterbury Christ Church University
    Tunbridge Wells, Kent TN1 2YG, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04117906
Lead sponsor
Canterbury Christ Church University
Responsible party
Sponsor
First posted
Oct 7, 2019
Start date
Nov 2, 2019
Primary completion
Jan 10, 2020
Completion
Jan 10, 2020
Last update
Aug 20, 2020

Study contacts

Asuka Boyle, MSc
principal investigator · Canterbury Christ Church University
Fergal Jones, PhD, PsychD
study director · Canterbury Christ Church University
Emma Travers-Hill, PhD, PsychD
study director · Kent and Medway NHS and Social Care Partnership Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion